# US 2012/0253036 A1 · Agent for treating fibromyalgia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253036 A1
- Document ID: US20120253036A1
- Status: Published application
- Kind: A1
- Application number: 13/514,870
- Filed: 2010-12-10
- Published: 2012-10-04
- Earliest claimed: 2009-12-11
- Inventors: Yukinori Nagakura; Mina Tsukamoto; Tomonari Watabiki
- Web page: https://patentgrep.com/patent/US20120253036A1

## CPC

- C07D 491/04: Ortho-condensed systems
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/415: 1,2-Diazoles
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 209/52: condensed with a ring other than six-membered
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 223/04: with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 239/70: condensed with carbocyclic rings or ring systems
- C07D 307/81: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 311/04: Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D 471/04: Ortho-condensed systems
- C07D 471/06: Peri-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/06: Peri-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 513/06: Peri-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An agent for treating fibromyalgia containing a 5-HT2C receptor agonist as an active ingredient

## Claims

### Claim 1

An agent for treating fibromyalgia, comprising:
a 5-HT2C receptor agonist as an active ingredient.

### Claim 2 (depends on 1)

The treatment agent according to claim 1,
wherein the active ingredient is a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof,
(symbols in the formula mean the following:
ring Y represents an unsaturated 5-membered hetero ring which may have 1 to 3 of one or two or more kinds of hetero atoms selected from N, O and S atoms, or represents an unsaturated 6-membered hetero ring having 1 to 2 N atoms;
X represents a bond or C;
V represents N or CH;
A represents linear or branched C1-6 alkylene which may be substituted with halogen or C3-8 cycloalkyl;
R1 and R2 may be the same as or different from each other and represent H or C1-6 alkyl, alternatively, R1 and R2 or R1 and A may form a 3- to 8-membered nitrogen-containing saturated hetero ring together with an N atom to which R1 and R2 or R1 and A bind;
R3 and R4 may be the same as or different from each other and represent H, C1-6 alkyl, OH, C1-6 alkyl-O—, amino, C1-6 alkyl-NH—, (C1-6 alkyl)2-N—, C1-6 alkyl-CO—NH—, or halogen;
R5 to R9 may be the same as or different from each other and represent H, C1-6 alkyl, OH, or C1-6 alkyl-O—; and
the portion of a dotted line represents an arbitrary double bond;
provided that when the portion of a dotted line is a double bond, R6 and R8 do not exist, and when X is a bond, the portion of a dotted line is a single bond, and R7 and R8 do not exist).

### Claim 3 (depends on 2)

The according to claim 2,
wherein the active ingredient is a compound represented by the following Formula (I′) or a pharmaceutically acceptable salt thereof,
(symbols in the formula mean the following:
R11, R12, R14, and R15 may be the same as or different from each other and represent H or C1-6 alkyl; and
R13 represents C1-5 alkyl).

### Claim 4 (depends on 3)

The treatment agent according to claim 3,
wherein the active ingredient is one of the following compounds or a pharmaceutically acceptable salt thereof:
(S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine;
(S)-2-(7-ethyl-3-methyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine;
(S)-2-(3,7-diethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine;
(S)-1-methyl-2-(7-propyl-1H-furo[2,3-g]indazol-1-yl)ethylamine;
(S)—N-ethyl-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-methylethylamine;
(S)-2-(4,7-diethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine;
(S)-2-(7-butyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine; or
(S)-2-(7-isopentyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine.

### Claim 5 (depends on 4)

The treatment agent according to claim 4,
wherein the active ingredient is (S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The treatment agent according to claim 1,
wherein the active ingredient is a compound represented by the following Formula (II) or a pharmaceutically acceptable salt thereof,
(symbols in the formula mean the following:
R21 represents H or C1-8 alkyl;
R22 represents C1-8 alkyl, —CH2—O—C1-8 alkyl, —C(═O)—O—C1-8 alkyl, —C(═O)—NH—C1-8 alkyl, OH, or CH2OH;
R22a represents H, alternatively, R22 and R2a form —CH2—CH2— together;
R23 represents halogen, perhalo-C1-8 alkyl, CN, —SR25, —NHR25, —N(R25)2, aryl, or heteroaryl, wherein the aryl may be optionally substituted with one or two substituents selected from Ci-8 alkyl, halogen, perhalo-C1-8 alkyl, and C1-8 alkyl-O—, and the heteroaryl may be optionally substituted with one or two substituents selected from halogen and C1-8 alkyl;
R24 represents H, halogen, perhalo-C1-8 alkyl, CN, —SR25, —NHR25, —N(R25)2, aryl, or heteroaryl, wherein the aryl may be optionally substituted with one or two substituents selected from C1-8 alkyl, halogen, perhalo-C1-8 alkyl, and C1-8 alkyl-O—, and the heteroaryl may be optionally substituted with one or two substituents selected from halogen and C1-8 alkyl;
alternatively, R23 and R24 may form a 5- or 6-membered hetero ring having one O atom together with an atom to which R23 and R24 bind;
R25 independently represents C1-8 alkyl, C1-8 alkenyl, aryl, heteroaryl, aryl-C1-8 alkyl-, heteroaryl-C1-8 alkyl- or perhalo-C1-8 alkyl, or allyl; and
R26 represents H or C1-8 alkyl;
provided that when R26 is C1-8 alkyl, R24 represents a group other than H).

### Claim 7 (depends on 6)

The treatment agent according to claim 6,
wherein the active ingredient is one of the following compounds or a pharmaceutically acceptable salt thereof,
8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-iodo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-trifluoromethyl-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-trifluoromethyl-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-chloro-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-bromo-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-iodo-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
7,8-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
7,8-dichloro-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; or 8-chloro-7-fluoro-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

### Claim 8 (depends on 7)

The treatment agent according to claim 7,
wherein the active ingredient is (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The treatment agent according to claim 1,
wherein the active ingredient is a compound represented by the following Formula (III) or a pharmaceutically acceptable salt thereof,
(in the formula,
R31 represents H, C1-6 alkyl, C1-5 alkyl-C(═O)—, or phenyl-C1-6 alkyl-O—C(═O)—;
each of R32 and R33 independently represents H, OH, C1-6 alkyl, C1-6 alkyl-O—, halogen, NH2—C(═O)—, C1-5 alkyl-O—C(═O)—, perfluoro-C1-6 alkyl, cyano, C1-6 alkyl-S(O)2—NH—, C1-6 alkyl-S(O)2—, C1-5 alkyl-C(═O)—NH—, amino, C1-6 alkyl-NH—, (C1-6 alkyl)2-N—, perfluoro-C1-6 alkyl-O—, C1-5 alkyl-C(═O)—O—, C1-5 alkyl-C(═O)—, phenyl-C(═O)—, phenyl, phenyl-C1-6 alkyl-, heteroaryl, or heteroaryl-C1-6 alkyl-, wherein a phenyl or heteroaryl portion of all substituents having the phenyl or heteroaryl portion may be substituted with 1 to 3 substituents independently selected from halogen, C1-6 alkyl, or C1-6 alkyl-O—;
each of R34 and R35 independently represents H or C1-6 alkyl, alternatively, R34 and R35 may form a cyclic portion selected from monocyclic C4-8 alkane, monocyclic C4-8 alkene, bridged bicyclic C5-10 alkane, bridged bicyclic C5-10 alkene, pyran, and thiopyran (wherein, a S atom may be oxidized to SO or SO2) together with carbon to which R34 and R35 bind, wherein the cyclic portion formed by R34 and R35 may be substituted with 1 to 3 substituents selected from halogen, C1-6 alkyl, and C1-6 alkyl-O—;
each of R36 and R37 independently represents H or C1-6 alkyl; and
n represents 1 or 2;
provided that, the portion of a dotted line represents an arbitrary double bond;
wherein, heteroaryl means a 5- to 7-membered monocyclic aromatic ring group having 1 or 2 hetero atoms selected from N, O, and S).

### Claim 10 (depends on 9)

The treatment agent according to claim 9,
wherein the active ingredient is one of the following compounds or a pharmaceutically acceptable salt thereof,
4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline;
2-bromo-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline;
2-chloro-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline;
2-phenyl-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline;
2-methoxy-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline;
1-fluoro-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino [6,7,1-ij]quinoline;
1-(trifluoromethyl)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline; or
1-fluoro-2-methoxy-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline.

### Claim 11 (depends on 10)

The treatment agent according to claim 10,
wherein the active ingredient is (−)-(9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The treatment agent according to claim 1,
wherein the active ingredient is
(S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine;
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
(−)-(9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline;
or a pharmaceutically acceptable salt thereof.
